Neoplasms

Respiratory Tract (Lung and Bronchial) Diseases

All Conditions

Lung Neoplasms

Carcinoma, Non-Small-Cell Lung

Carcinoma

Respiratory Tract Neoplasms

Thoracic Neoplasms

Lung Diseases

Respiratory Tract Diseases

Carcinoma, Bronchogenic

Bronchial Neoplasms

Micronutrients

All Drugs and Chemicals

Cobalt

Proton radiation with concomitant chemotherapy

Proton radiation at 2 cobalt gray equivalent per fraction to a total of 74 cobalt gray equivalent with concomitant weekly chemotherapy.

PET positive nodal disease measuring 15 mm or greater

Proton radiation at 2 cobalt gray equivalent per fraction to a total of 60 cobalt gray equivalent with concomitant weekly chemotherapy.

PET positive nodal disease measuring less than 15 mm

Proton radiation at 2 cobalt gray per fraction. Re-evaluation performed between days 18-22 of treatment. If considered resectable after re-evaluation, radiotherapy will discontinue after a total of 50 cobalt gray equivalent and surgery will be performed.

Patients considered resectable

Bradford S Hoppe, MD, MPH

The purpose of this study is to find out what effects, good and/or bad, proton radiation at a higher tumor dose (and lower normal surrounding lung dose) combined with standard chemotherapy has on lung cancer. The dose you receive to the tumor will be higher than the standard dose. This may be able to increase the control of the tumor. Due to the accuracy of radiation given with protons, the dose to the normal lung tissue that surrounds the tumor will be lower than standard. This may be able to reduce the frequency and severity of the usual radiation side effects.

Proton Therapy With Chemotherapy for Stage III Non-Small Cell Lung Cancer (LU02)

A Phase II Trial of 3 Dimensional Proton Radiotherapy With Concomitant Chemotherapy for Patients With Initially Unresectable Stage III Non-Small Cell Lung Cancer

Disease control rate is defined as Complete Response (CR) + Partial Response (PR) + Stable Disease (SD). As per RECIST version 1.1, Complete Response (CR): Disappearance of all target lesions, Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters, Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study."), as accurate.

University of Florida

Proton radiation with concomitant chemotherapy

PET positive nodal disease measuring 15 mm or greater: Proton radiation at 2 cobalt gray equivalent per fraction to a total of 74 cobalt gray equivalent with concomitant weekly chemotherapy.

PET Positive Nodal Disease Measuring 15 mm or Greater

Proton radiation

PET positive nodal disease measuring less than 15 mm: Proton radiation at 2 cobalt gray equivalent per fraction to a total of 60 cobalt gray equivalent with concomitant weekly chemotherapy.

PET Positive Nodal Disease Measuring Less Than 15 mm

Proton radiation plus surgery

Patients considered resectable: Proton radiation at 2 cobalt gray per fraction. Re-evaluation performed between days 18-22 of treatment. If considered resectable after re-evaluation, radiotherapy will discontinue after a total of 50 cobalt gray equivalent and surgery will be performed.

Patients Considered Resectable

Total

Age, Categorical

Age, Continuous

Sex: Female, Male

United States

Region of Enrollment

Bradford Hoppe, M.D.

Grade 3 or Higher Rate of Non-hematologic, Acute Treatment-related Toxicities

Thirteen enrolled patients that completed treatment

Percentage of Patients With Disease Control

Thirteen enrolled patients that completed treatment.

Percentage of Patients Alive at 5 Years

This data was not collected as study was terminated early.

Spots Global Cancer Trial Database for pet positive nodal disease measuring 15 mm or greater